Core Viewpoint - The MSCI China Healthcare Index has increased by 59.5% year-to-date, outperforming the MSCI China Index by 24%, but has recently experienced a correction of approximately 10% since early October, indicating that some stocks are undervalued and still attractive for investment [1] Group 1: Market Performance - The MSCI China Healthcare Index has shown a significant year-to-date increase of 59.5% [1] - This index has outperformed the MSCI China Index by 24% [1] - The healthcare sector has seen a recent correction, with a decline of about 10% since early October [1] Group 2: Investment Recommendations - The report highlights several companies with "buy" ratings, including: - 3SBio (01530) - Genscript Biotech (02273) - Junshi Biosciences (02367) - WuXi AppTec (02268) - Innovent Biologics (01801) - China Biologic Products (01177) [1] Group 3: Market Outlook - The capital market is expected to see a recovery in financing activities [1] - There is an anticipated expansion in the overseas trading scale of innovative drugs [1] - Domestic demand for innovative drug research and development is expected to rebound [1] - The U.S. entering a rate-cutting cycle may lead to a recovery in the performance of CXO companies in the second half of the year [1] - The clinical development of authorized innovative drug pipelines overseas is expected to be a significant catalyst for the innovative drug sector [1]

Core Viewpoint - The MSCI China Healthcare Index has increased by 59.5% year-to-date, outperforming the MSCI China Index by 24%, but has recently experienced a correction of approximately 10% since early October, indicating potential investment opportunities in undervalued stocks [1] Group 1: Market Performance - The MSCI China Healthcare Index has shown a significant year-to-date increase of 59.5% [1] - This index has outperformed the MSCI China Index by 24% [1] - The healthcare sector has seen a recent correction, with a decline of about 10% since early October [1] Group 2: Investment Recommendations - Certain stocks are considered undervalued and attractive, including: - 3SBio Inc. (01530) - Genscript Biotech Corporation (02273) - Junshi Biosciences (02367) - WuXi AppTec Co., Ltd. (02268) - Innovent Biologics, Inc. (01801) - China National Pharmaceutical Group (01177) - All the mentioned stocks have been given a "Buy" rating [1] Group 3: Market Outlook - The capital market is expected to see a recovery in financing activities [1] - There is an anticipated expansion in the trading scale of innovative drugs overseas [1] - Domestic demand for innovative drug research and development is expected to rebound [1] - The U.S. entering a rate-cutting cycle may lead to a recovery in the performance of CXO companies in the second half of the year [1] - The clinical development of authorized innovative drug pipelines overseas is expected to be a significant catalyst for the innovative drug sector [1]

Core Insights - Sino Biopharmaceutical Limited and Shanghai MediTrust Health Technology Group signed a strategic cooperation agreement to enhance access to innovative drugs and commercial insurance, aiming for drug-insurance integration [1][5] Company Overview - Sino Biopharm generates annual revenue of approximately RMB 30 billion and ranks 38th among the Top 50 Global Pharmaceutical Companies, with a pipeline of over 120 innovative drugs [3] - MediTrust Health focuses on transforming China's healthcare payment system, leveraging AI and data-driven solutions to improve the "diagnosis-treatment-payment" journey [7] Strategic Goals - The partnership aims to explore AI, data collaboration, and innovative payment solutions to set new benchmarks for industry coordination [4] - The collaboration aligns with the "Healthy China 2030" strategy, enhancing drug accessibility and creating a win-win ecosystem for the pharmaceutical and insurance sectors [5] Financial Impact - MediTrust Health has serviced approximately 393 million commercial health insurance policies, achieving cumulative savings of RMB 6.7 billion in out-of-pocket costs for patients [7]

Summary of Sino Biopharmaceutical (1177.HK) Conference Call Company Overview - **Company**: Sino Biopharmaceutical - **Ticker**: 1177.HK - **Industry**: Pharmaceuticals, Biotech, and Medtech Key Points Product Sales Growth - Management reported an encouraging trend in product sales growth in 3Q, showing acceleration compared to 1H25, primarily driven by new products such as gasorasib (KRAS G12C), factor Ⅶa, and meloxicam [2][3] - Earnings growth is expected to outpace topline growth due to investment gains [2] Financial Highlights - A milestone payment of **US$300 million** from Merck to LaNova has been received, which will be recorded in 2H25 after sharing **25%** with Genscript and tax deductions [2] - The company has a cost advantage of **20%-50%** lower than peers due to scale effects of large pharma [2] Regulatory and Market Considerations - For biosimilar VBP, management expressed low expectations for nationwide execution due to potential supply issues and a shift in policymakers' focus towards drug quality [2] - Smooth progress was noted in NRDL renewal negotiations for anlotinib, KRAS G12C, and PD-1 [2] Business Development Goals - The company aims to close a major licensing deal with upfront payments exceeding **US$100 million** by the end of 2025, emphasizing improved experience in business development negotiations [3] - Promising assets in the pipeline include: - **LM-108**: Potential first-in-class CCR8 mAb - **AP025 (FGF21)**: Global rights obtained from Ampsource Bio, potentially better efficacy for MASH, could be developed with GLP-1 - **PD-1/IL2**: Targeting IND in 2026 with a potentially better safety profile - **EGFR/cMET bispecific antibody**: Phase 1 clinical data readout expected in 2026 - **PD-1/CTLA-4 bispecific**: Broader therapeutic window anticipated [3] Price Target and Risks - The 12-month SOTP-based price target is **HK$6.19**, with a current price of **HK$7.12**, indicating a downside of **13.1%** [7][8] - Key downside risks include: - Broader price cuts on the generics portfolio - Delays in regulatory approvals for key products - Low returns on R&D investments due to resource allocation issues - Below-expectation ramp-up of innovative drugs [7] Market Capitalization and Financial Metrics - Market capitalization stands at **HK$134.4 billion** (approximately **US$17.3 billion**) [8] - Revenue projections for the next few years are as follows: - **2024**: **28,866.2 million RMB** - **2025E**: **33,640.4 million RMB** - **2026E**: **35,858.2 million RMB** - **2027E**: **38,682.4 million RMB** [8] Analyst Ratings - The company is rated as a "Buy" by Goldman Sachs, with a focus on its innovative pipeline and growth potential [8] Additional Considerations - The report includes disclosures regarding potential conflicts of interest due to Goldman Sachs' business relationships with the company [4][17] - Analysts emphasize the importance of considering this report as one of several factors in investment decisions [4]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生物製藥有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01177 | 說明 | - | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.025 HKD | | 750,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | 30,000,000,000 | | HKD | | 0.025 HKD | | 750,000,000 | 本月底法定/註冊股本總額： ...

Core Insights - The 12th China Healthcare Summit, co-hosted by BioCentury and BayHelix, highlighted the significant acquisition of Lixian Pharmaceutical by China National Pharmaceutical for approximately $1 billion, earning the "Company of the Year" award for 2025 [1][2] - The summit showcased the record-breaking foreign licensing deals in China's innovative drug sector, surpassing $100 billion for the first time in a single year, reflecting the growing maturity of China's biopharmaceutical technology [1] Group 1: Acquisition Highlights - The acquisition of Lixian Pharmaceutical by China National Pharmaceutical is noted as a rare instance of a domestic company acquiring a local innovator within China's evolving biotech ecosystem [2] - This deal grants China National Pharmaceutical access to eight clinical projects, including a dual-target PD-1x VEGF antibody, which has already attracted significant global interest [2][3] - The acquisition is viewed as a milestone in the history of China's biopharmaceutical development, marking a key sign of the industry's maturation and upgrade [2] Group 2: R&D Progress - Following the acquisition, Lixian Pharmaceutical has accelerated its R&D progress, with two indications for the new drug LM-302 (CLDN18.2ADC) included in the breakthrough therapy category by the National Medical Products Administration [3] - The dual-target antibody LM-24C5 has received approval to commence Phase II clinical trials for advanced solid tumors, while the ADC drug LM-350 has successfully completed patient enrollment in a Phase I trial in Australia [3]

Core Insights - China National Pharmaceutical Group received the "Company of the Year" award at the 2025 BayHelix Awards due to its significant acquisition of Lixian Pharmaceutical for approximately $1 billion [1] - The acquisition is notable as it marks a domestic pharmaceutical company acquiring a local innovator within China's evolving biotech ecosystem [1] - This transaction enabled China National Pharmaceutical Group to gain access to eight clinical projects [1]

Core Insights - Morgan Stanley's research report indicates that Innovent Biologics has announced a global collaboration agreement with Takeda Pharmaceutical, involving an upfront payment of $1.2 billion and potential milestone payments of up to $11.4 billion, making it the second-largest out-licensing deal globally based on transaction value [1] Group 1 - The agreement involves the joint development of IBI363, with commercialization in the U.S. market, where research and profit/loss will be shared in a 60/40 ratio [1] - Innovent grants Takeda commercialization rights outside Greater China and the U.S., with Takeda responsible for potential development and sales milestone payments, as well as royalties [1] Group 2 - The arrangement is expected to strengthen Innovent's market position in the U.S. and develop the capabilities needed for independent global clinical development and commercialization [1] - Morgan Stanley reaffirms Innovent Biologics as a preferred choice in China's biopharmaceutical sector, setting a target price of HKD 110 and maintaining an "Overweight" rating [1]

Core Insights - China Biopharmaceutical announced the interim analysis results of the Phase III clinical trial (CULMINATE-2) for its innovative drug, Kumosili capsules, presented at the 2025 European Society for Medical Oncology (ESMO) [1] - CULMINATE-2 is the first global Phase III trial demonstrating positive results for an oral CDK2/4/6 inhibitor combined with endocrine therapy for HR+/HER2- advanced breast cancer [1] Group 1 - Kumosili is a novel oral CDK2/4/6 inhibitor with varying degrees of inhibition on CDK2, CDK4, and CDK6, showing strong selectivity against CDK4, which may help delay clinical resistance and reduce bone marrow suppression [2] - The China National Medical Products Administration (NMPA) accepted the marketing application for Kumosili combined with Fulvestrant for previously treated HR+/HER2- locally advanced or metastatic breast cancer in July 2024, with a second indication application expected in July 2025 [2] - The company is actively advancing a Phase III clinical trial for Kumosili in adjuvant therapy for breast cancer, having completed patient enrollment, with plans to submit a marketing application in the next two years [2] Group 2 - Kumosili is expected to comprehensively cover the treatment cycle for HR+/HER2- breast cancer, including first-line, subsequent lines, and adjuvant therapy, providing innovative treatment options for more patients [2]

Core Insights - China Biologic Products (01177) announced the mid-analysis results of the Phase III clinical trial (CULMINATE-2) for its innovative drug, Kumosili capsules (CDK2/4/6 inhibitor), for first-line treatment of HR+/HER2- advanced breast cancer at the 2025 European Society for Medical Oncology (ESMO) [1] - CULMINATE-2 is the first global Phase III trial demonstrating positive results for an oral CDK2/4/6 inhibitor combined with endocrine therapy in HR+/HER2- advanced breast cancer [1] - Kumosili shows selective inhibition of CDK4 kinase, which may help delay clinical resistance and reduce bone marrow suppression, potentially positioning it as a Best-in-Class therapy [1] Regulatory Developments - The Center for Drug Evaluation (CDE) of the National Medical Products Administration has accepted the marketing application for Kumosili combined with Fulvestrant for previously treated HR+/HER2- locally advanced or metastatic breast cancer, expected to be reviewed by July 2024 [2] - A second indication for initial endocrine treatment in HR+/HER2- locally advanced or metastatic breast cancer is also under review, with an expected decision by July 2025 [2] - The company is advancing a Phase III clinical trial for Kumosili in adjuvant therapy, with all participants enrolled and a marketing application anticipated within the next two years [2] Market Potential - Kumosili is expected to comprehensively cover the treatment cycle for HR+/HER2- breast cancer, including first-line, subsequent lines, and adjuvant therapy, providing innovative treatment options for more patients [2]